EICHOR
● Active Not Recruiting
Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)
Condition: Advanced or Metastatic Renal Cell Carcinoma · Sponsor: Ipsen
About this study
The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of treatment)
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (20)
| Onze-Lieve-vrouw Ziekenhuis Aalst | Aalst, Belgium | — |
| Imeldaziekenhuis | Bonheiden, Belgium | — |
| Clinique Saint-Luc Bouge | Bouge, Belgium | — |
| AZ Sint-Jan Brugge | Bruges, Belgium | — |
| AZ Sint-Lucas | Bruges, Belgium | — |
| UZ Brussel | Brussels, Belgium | — |
| Ziekenhuis Oost-Limburg Genk | Genk, Belgium | — |
| Universitair Ziekenhuis Gent | Ghent, Belgium | — |
| Hôpital de Jolimont | La Louvière, Belgium | — |
| CHC MontLegia | Liège, Belgium | — |
| CHR Citadelle Liège | Liège, Belgium | — |
| CHU Liège / Sart-Tilman | Liège, Belgium | — |
+ 8 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04106349